Synthesis of anthraquinone-ibuprofen prodrugs with hydroxyapatite affinity and anti-inflammatory activity characteristics

Medicinal Chemistry

Volumn 5, Issue 6, 2009, Pages 577-582

  Duan, Yanbing ^a   Yu, Jia ^a   Liu, Shi ^b   Ji, Min ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b Yangtze River Pharmacy Group Nanjing Hailing Pharmaceutical Co Ltd   (China)

Author keywords

Anti inflammatory; Bone affinity; Bone targeting; Hydrolysis; Hydroxyapatite; Prodrug

Indexed keywords

ANTHRAQUINONE; HYDROXYAPATITE; IBUPROFEN; PRODRUG; RHEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG HYDROLYSIS; DRUG RELEASE; DRUG STRUCTURE; DRUG SYNTHESIS; EXTERNAL EAR; IN VITRO STUDY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANIMALS; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BONE AND BONES; DURAPATITE; EAR AURICLE; ESTERS; HYDROLYSIS; IBUPROFEN; MALE; MICE; PRODRUGS;

EID: 75749128637     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609790170498     Document Type: Article

References (27)

1. Dharap, S.S.; Wang, Y.; Chandna, P.; Khandare, J.J.; Qiu, B.; Gunaseelan, S.; Sinko, P.J.; Stein, S.; Farmanfarmaian, A.; Minko, T. Tumor-spectific targeting of an anticancer drug delicery system by LHRH peptide Proc. Natl.Acad. Sci., 2005, 102, 12962-7.
2. Perrin, D.D. Binding of tetracyclines to bone. Nature, 1965, 208, 787-8.
3. Beccerica, E.; Ferretti, G.; Curatola, G.; Cervini, C. Diacetylrhein and rhein: in vivo and in vitro effect on lymphocyte membrane fluidity. Pharmacol. Res., 1990, 22, 227-85.
4. Itokawa, H.; Susan, L.; Natschke, M.; Akiyama, T.; Lee, K.H. Plant-derived natural product research aimed at new drug discovery. J Nat. Med., 2008, 62, 263-80.
5. Tamuraa, T.; Shiraia, T.; Kosakaa, N.; Ohmoria, K.; Takafumi. N. Pharmacological studies of diacerein in animal models of inflammation, arthritis and bone resorption. Eur. J. Pharmacol., 2002, 448, 81-7.
6. Debord, P.; Louchahi, K.; Tod, M.; Cournot, A.; Perret, G.; Petitjean, O. Influence of renal function on the pharmacokinetics of diacerein after a single oral dose. Eur. J. Drug Metab. Pharmacokinet., 1994, 19, 13-9.
7. Tamura, T.; Kosaka, N.; Ishiwa, J.; Sato, T.; Nagase, H.; Ito, A. Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1,-3,-9 and -13 and upregulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes. Osteoarthritis Cartilage, 2001, 9, 257-63.
8. Spencer C.M., Wilde M.I. Diacerein. Drugs, 1997, 53, 98-106.
9. Moore A.; Greenslade K.; Alam C.; Willoughby, D. Effect of diacerhein on granuloma induced cartilage breakdown in the mouse. Osteoarthritis Cartilage, 1998, 6, 19-23.
10. Pelletier, J.P.; Lajeunesse, D.; Reboul, P.; Mineau, F.; Fernandes, J.C.; Sabouret, P.; Martel-Pelletier, J. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol., 2001, 28, 814-24.
11. Mian, M.; Brunelleschi, S.; Tarli, S.; Rubino, A.; Benetti, D.; Fantozzi, R.; Zilletti, L. Rhein: an anthraquinone that modulates superoxide anion production from human neutrophils. J. Pharm Pharmacol., 1987, 39, 845-7.
12. Tamura, T.; Ohmori, K. Diacerein suppresses the increase in plasma nitric oxide in rat adjuvant-induced arthritis. Eur. J. Pharmacol., 2001, 419, 269-74.
13. Povoroznyuk, V.; Dzerovych, N. Effectiveness of complex medication (glucosamine, chondroitin sulphate and ibuprofen) for treatment of pain syndrome under knee osteoarthritis. R. Anesth. Pain Med., 2008, 33, e213.
14. Heyneman, C.; Lawless-Liday, C.; Wall, G. Oral versus topical NSAIDs in rheumatic disease: a comparison. Drugs, 2000, 60, 555-74.
15. Giammona, G.; Puglisi, G.; Carlisi, B.; Pignatello, R.; Spadaro, A.; Caruso, A. Polymeric prodrugs: α,β-poly(N-hydroxyethyl)-DL- aspartamide as a macromolecular carrier for some non-steroidal anti-inflammatory agents. Int. J. Pharm., 1989, 57, 55-62.
16. Lombardino, G. Non-steroidal Anti-inflammatory Drugs, Wiley: New York, 1985.
17. Tammara, V.K.; Narurkar, M.M.; Crider, A.M.; Khan, M.A. Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. Pharm. Res., 1993, 10, 1191-9.
18. Shanbag, V.R.; Crinder, A.M.; Gokhale, R.; Harpalini, A.; Dick, R.M. Ester and amide prodrugs of ibuprofen and naproxen: Synthesis, anti-inflammatory activity, and gastrointestinal toxicity J. Pharm. Sci., 1992, 81, 149-54.
19. Saari, W.S.; Freedam, M.B.; Hartman, R.D.; King, S.W.; Raab, A.W.; Randa, W.C.; Engelhardt, E.L.; Hitschmann, R.; Rosegay, A. Synthesis and antihypertensive activity of some ester progenitors of methyldopa. J. Med. Chem., 1978, 21, 746-53.
20. Khan, M.; Akther, M. Synthesis, pharmacological activity and hydrolytic behavior of glyceride prodrugs of ibuprofen. Eur. J. Med. Chem., 2005, 40, 371-6.
21. Cocco, M.T.; Congiu, C.; Onnis, V.; Morelli, M.; Cauli, O. Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur. J. Med. Chem., 2003, 38, 513-8.
22. Mahfouz, N.M.; Omar, F.A.; Fadl, T. Cyclic amide derivatives as potential prodrugs II: N-hydroxymethylsuccinimide-/ isatin esters of some NSAIDs as prodrugs with an improved therapertic index. Eur. J. Med. Chem., 1999, 34, 551-62.
23. Moller, N.; Dietzel, K.E.; Schneider, H.T.; Brune, K. Novel 5-aminosalicylic acid NSAID conjugates: synthesis; pharmacological and toxicological properties. Eur. J. Med. Chem., 1989, 24, 463-9.
24. Duan, Y.; Yu, J.; Liu, H.; Ji, M. Determination of anthraquinone prodrug and its hydrolytic active compounds using RP-HPLC. J. Southeast Univ. (Eng. Edit.), 2009, 25, 128-31.
25. Fonteneaua, N.; Martina, P.; Mondona, M.; Ficheuxb, H.; Gesson, J.P. Synthesis of quinine and xanthone analogs of rhein. Tetrahedron, 2001, 57, 9131-5.
26. Duan, Y.; Yu, J.; Liu, H.; Ji, M. Bone-targeting anthraquinone-diclofenac prodrugs with hydrolytic and bone affinity characteristics. Lett. Drug Des. Discov., 2009, 6, 393-6.
27. Erez, R.; Ebner, S.; Attali, B.; Shabat, D. Chemotherapeutic bone-targeted bisphosphonate prodrugs with hydrolytic mode of activation. Bioorg. Med. Chem. Lett., 2008, 18, 816-20.